As antibody-drug conjugates (ADCs) continue to move into more complex payload classes and higher drug–antibody ratios, linker and conjugation chemistry remains a critical bottleneck for clinical success. In response to these challenges, the 4th ADC Linker & Conjugation Summit has released its 2026 agenda, confirming its return to Boston this July as the only meeting dedicated exclusively to advancing linker and conjugation strategies in ADC development.
Designed specifically for specialists working at the cutting edge of ADC chemistry, the summit provides a highly technical, deeply curated environment where attendees are not lost in a broad oncology crowd. Instead, participants are surrounded by peers with the same job titles, scientific focus, and day‑to‑day challenges, ensuring every session, discussion, and connection is directly relevant to real chemistry decision‑making.
View the full 2026 agenda here: https://ter.li/qtyb6433
A Technical Program Built for ADC Chemistry Specialists
Over three focused days, the 2026 program explores the chemistry shaping the next generation of ADCs, with sessions covering:
- Dual‑payload ADC design and high‑DAR construct engineering
- Managing hydrophobicity and aggregation risk
- Novel linker architectures to improve tumor selectivity and therapeutic index
- Emerging conjugation strategies enabling new modalities and payload classes
With 17 new speakers and 13 new companies represented, the 2026 faculty reflects the rapidly evolving ADC landscape and the growing need for chemistry-led innovation.
- Manel Merabet, Chief Development Officer, SKYMAB Biotherapeutics
- Paul Sauter, Senior Director, Chemistry & Bioconjugation, VERAXA
- Tara Arvedson, Chief Scientific Officer, Hexagon Bio
- Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics
- Sujiet Puthenveetil, Director of Antibody Drug Conjugates & Radioconjugates, AstraZeneca
- Michael Torres, Chief Executive Officer, CrossBridge Bio
Explore the full speaker lineup: https://ter.li/qtyb6433
Interactive Workshops Addressing Translational Performance Gaps
A major focus for 2026 is the introduction of new interactive workshops, responding directly to industry demand for deeper, application‑driven discussion. These workshops will allow attendees to:
- Better connect linker and conjugation chemistry with translational and in vivo performance
- Explore strategies to reengineer traditional payloads using next‑generation linker and conjugation technologies
- Share practical learnings with peers facing similar scale‑up, stability, and toxicity challenges
By combining technical case studies with interactive discussion, the workshops are designed to move beyond theory and toward actionable chemistry solutions.
A Curated Forum for Real ADC Chemistry Progress
The 4th ADC Linker & Conjugation Summit will welcome 80+ ADC chemists, biologists, and platform innovators, creating a focused forum where every conversation is relevant and every session is designed to advance practical development strategies.
Unlike larger, more general ADC events, this summit is built entirely around the needs of linker and conjugation specialists, enabling meaningful peer‑to‑peer exchange and highly targeted scientific debate.
About the ADC Linker & Conjugation Summit
Produced by Hanson Wade, the ADC Linker & Conjugation Summit is the leading technical meeting dedicated exclusively to linker and conjugation chemistry in antibody‑drug conjugates.
For more information, visit: https://ter.li/f00hhz7d